Lactic acid bacteria with high expression of human III-type collagen and application of lactic acid bacteria

By designing and expressing nucleic acid molecules of human type III collagen in lactic acid bacteria, the problem of the difference in the nutritional composition of animal extracts with viruses and Saccharomyces cerevisiae in existing collagen production is solved, and efficient and safe collagen production is achieved. The promotion and application of beneficial ingredients of lactic acid bacteria has reduced production costs and time.

CN118891369APending Publication Date: 2024-11-01BESMATE BIOTECHNOLOGY (ZHEJIANG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380017450.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-08
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing collagen production methods have hidden dangers of viral health in animal extracts, high cost of animal cell culture and long cycles, and health risks of endotoxins in E. coli. The nutritional components of Saccharomyces cerevisiae and lactic acid bacteria are different, and the lack of hydrolytic enzymes unique to lactic acid bacteria is difficult. Achieve efficient and safe collagen production.

Method used

By designing and expressing nucleic acid molecules encoding human type III collagen, a recombinant expression vector is constructed, and the lactic acid bacteria host cells are introduced, and the expression is induced by using streptococcin in lactic acid bacteria is achieved. The production of highly expressed human type III collagen is achieved under conventional culture medium and conditions of lactic acid bacteria. .

Benefits of technology

It has achieved efficient and safe production of lactic acid bacteria extracts rich in human type III collagen, avoiding the health risks of endotoxins, and using the beneficial ingredients of lactic acid bacteria to promote and apply, reducing production costs and time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118891369A_ABST
    Figure CN118891369A_ABST
Patent Text Reader

Abstract

The invention discloses lactic acid bacteria for highly expressing human III-type collagen as well as a preparation method and application of the lactic acid bacteria. The lactic acid bacteria obtained by the invention can generate a large amount of human III-type collagen through induction under conventional culture medium and culture conditions. The lactic acid bacteria do not contain endotoxin and contain many active ingredients beneficial to human bodies, so that the collagen and lactic acid bacteria have important value for popularization and application of collagen and lactic acid bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bioengineering, and specifically relates to a lactic acid bacterium highly expressing human type III collagen and application thereof. Background Art

[0002] Collagen is an important protein component of the human body. Artificially prepared collagen has good biocompatibility, biodegradability and absorbability. It can promote the formation of new cells, wound healing and scar repair. It is widely used in the medical, beauty, cosmetics and health care products industries and has huge market potential. The current collagen production methods mainly use animal tissue extraction, animal cell culture expression, yeast or Escherichia coli heterologous expression. The process of extracting collagen from animal tissue includes three main steps: tissue dissolution, enzyme treatment and purification. The expression of animal cells, yeast or Escherichia coli mainly includes five steps: cell or bacterial expansion culture, induced expression, cell or bacterial concentration collection, extraction after lysis, and purification.

[0003] Collagen extracted from animal tissues may carry various viruses, so various products of animal extracts will cause serious health risks if used directly on the human body. The cost of animal cell culture is very expensive and the cycle is long, making it difficult to carry out industrial production. Escherichia coli is not an edible bacterium, and the endotoxins it contains pose a health risk, so the purification process is complicated and the cost is high. Brewer's yeast and other edible safe bacteria, but their nutritional components are different from those of lactic acid bacteria, and they lack various hydrolases unique to lactic acid bacteria. Summary of the invention

[0004] In view of the deficiencies of the prior art, the present invention provides a lactic acid bacterium capable of highly expressing human type III collagen fragments, so as to obtain an extract rich in human type III collagen fragments and lactic acid bacteria nutrients.

[0005] One aspect of the present invention provides an isolated nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO:2, or a sequence having more than 80%, more than 85%, more than 90%, more than 92%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, or more than 99.5% homology with the nucleotide sequence shown in SEQ ID NO:2.

[0006] In some embodiments, the nucleic acid molecule encodes human type III collagen, and the human type III collagen has the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence shown in SEQ ID NO: 1 after one or more amino acids are added, deleted, replaced or modified.

[0007] Another aspect of the present invention provides a recombinant expression vector containing the nucleic acid molecule of the present invention.

[0008] Another aspect of the present invention provides a host cell, wherein the host cell contains the nucleic acid molecule or the recombinant expression vector of the present invention.

[0009] In some embodiments, the host cell is a lactic acid bacterium.

[0010] In some embodiments, the host cell is Lactococcus lactis NZ3900 strain.

[0011] In some embodiments, the host cell can express type III collagen, and the type III collagen has the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence shown in SEQ ID NO: 1 after one or more amino acids are added, deleted, replaced or modified.

[0012] Another aspect of the present invention provides a primer pair for PCR amplification of the nucleic acid molecule of the present invention, the primer pair comprising:

[0013] Forward primer: CTAGCCATGGGCGAAAATCTTTATTTTCAAGGAGGA (SEQ ID NO: 3),

[0014] Reverse primer: CAAGAAGCTTAACTTCGCCCTTGGCACC (SEQ ID NO: 4).

[0015] Another aspect of the present invention provides the use of the nucleic acid molecule, the recombinant expression vector, the host cell and the primer pair of the present invention in the production of human type III collagen.

[0016] Another aspect of the present invention provides a method for preparing human type III collagen, the method comprising the following steps:

[0017] 1) introducing the nucleic acid molecule of the present invention into a plasmid to obtain a recombinant plasmid;

[0018] 2) Transforming the recombinant plasmid into host cells, culturing and inducing expression, and purifying to obtain human type III collagen.

[0019] In some embodiments, in step 1), the nucleic acid molecule further comprises a nucleotide sequence encoding a tag.

[0020] In some specific embodiments, the nucleic acid molecule comprises a nucleotide sequence encoding at least one His tag, for example, comprises 6 His tags.

[0021] In some embodiments, the host cell is a lactic acid bacterium.

[0022] In some embodiments, the host cell is Lactococcus lactis NZ3900 strain.

[0023] In some embodiments, the plasmid is pNZ8149 plasmid.

[0024] In some embodiments, the induction is performed using nisin. Preferably, the concentration of nisin is 5-20 μg / L, preferably 8-12 μg / L, and more preferably 10 μg / L.

[0025] In some embodiments, the induction temperature is 20-35°C, preferably 25-32°C, and more preferably 28-30°C.

[0026] In some embodiments, the induction time is 5-20 hours, preferably 5-15 hours, and more preferably 8-12 hours.

[0027] In some embodiments, the culture uses a conventional culture medium used in the art for culturing lactic acid bacteria, such as M17 culture medium.

[0028] In some embodiments, the culture temperature is 30-40°C, preferably 35-40°C, more preferably 37°C.

[0029] In some embodiments, the culture time is 5-30 h, preferably 10-20 h, and more preferably 12-16 h.

[0030] Another aspect of the present invention provides the use of type III collagen obtained by the preparation method of the present invention in the preparation of medicines, cosmetics or health products for promoting new cell formation, wound healing and scar repair.

[0031] The lactic acid bacteria provided by the present invention can produce a large amount of human type III collagen by induction under conventional culture medium and culture conditions. Since the lactic acid bacteria do not contain endotoxins and contain many active ingredients beneficial to the human body, they are of great value for the promotion and application of collagen and lactic acid bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The protein gel electrophoresis detection result obtained in step 5 of Example 1 of the present invention is shown.

[0033] Figure 2 The immunoblotting results obtained in step 6 of Example 1 of the present invention are shown. DETAILED DESCRIPTION

[0034] The following examples illustrate the present invention, but the present invention is not limited to these examples. Modifications to the specific embodiments of the present invention or equivalent replacement of some technical features without departing from the spirit of the present invention should be included in the scope of the technical solution claimed by the present invention.

[0035] The term "substitution" as used herein for amino acids refers to the replacement of at least one amino acid residue in an amino acid sequence by another different "replacement" amino acid residue. The term "insertion" as used herein for amino acids refers to the incorporation of at least one additional amino acid into an amino acid sequence. Although inserts typically consist of the insertion of 1 or 2 amino acid residues, larger "peptide inserts" can also be prepared, for example, inserting about 3 to 5 or even up to about 10, 15 or 20 amino acid residues. As disclosed above, the inserted residues can be naturally occurring or non-naturally occurring. The term "deletion" as used herein for amino acids refers to the removal of at least one amino acid residue from an amino acid sequence.

[0036] The enamel matrix protein of the present invention may comprise conservative amino acid substitutions at one or more amino acid residues, for example, at essential or non-essential amino acid residues. "Conservative amino acid substitutions" are amino acid residues replaced by amino acid residues having similar side chains. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, in the present invention, the essential or non-essential amino acid residues in the enamel matrix protein are preferably replaced with another amino acid residue from the same side chain family.

[0037] "Percent sequence identity" or "percent identity" between two polynucleotide or polypeptide sequences refers to the number of identical matching positions shared by the sequences within the comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matching position is any position where the same nucleotide or amino acid is present in both the target sequence and the reference sequence. Since a gap is not a nucleotide or amino acid, gaps present in the target sequence are not counted. Likewise, since target sequence nucleotides or amino acids are counted and nucleotides or amino acids from the reference sequence are not counted, gaps present in the reference sequence are not counted.

[0038] The sequence identity percentage can be calculated by the following process: determine the number of positions where the same amino acid residue or nucleic acid base occurs in both sequences to obtain the number of matching positions, divide the number of matching positions by the total number of positions in the comparison window, and multiply the result by 100 to obtain the sequence identity percentage. The determination of the sequence identity percentage between the comparison of the sequence and the two sequences can be completed using software that is easy to use and download online. Suitable software programs can be obtained from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining the sequence identity percentage is bl2seq, which is a part of the BLAST program suite that can be obtained from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. Government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used for comparing nucleic acid sequences, and BLASTP is used for comparing amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.

[0039] The present invention provides a method for preparing lactic acid bacteria that highly expresses human type III collagen. First, the full sequence of human type III collagen (protein retrieval number: P02461) is downloaded from the NCBI database, and a partial sequence is selected. A tag sequence that is easy to detect is added to the end for expression construction. A DNA sequence for collagen expression is designed according to the codon preference of lactic acid bacteria, and a biotechnology company is commissioned to synthesize it. The synthesized sequence is inserted into the multiple cloning site of a lactic acid bacteria expression vector through restriction enzyme digestion and ligation reaction to construct a recombinant vector. The recombinant vector is introduced into a lactic acid bacteria expression strain, and after obtaining a recombinant strain, liquid culture and induced expression are performed. The bacterial cells are collected, and protein gel electrophoresis and immunoblotting (western blot) are performed after lysis to confirm the high expression of the target protein.

[0040] In this example, no specific techniques or conditions are specified, and the operation is carried out according to the conventional techniques and instrument instructions in the art. The reagents or instruments used without specifying the manufacturer are all conventional products that can be obtained through commercial purchase.

[0041] Example 1 Preparation method of lactic acid bacteria that highly express human type III collagen

[0042] Step 1: Obtain the complete sequence of human type III collagen from the NCBI database (protein accession number: P02461), select part of the sequence for expression construction, and add a His tag for detection at the end of the sequence. The specific sequence is as follows:

[0043] GRPGRPGERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVHHHHHH (SEQ ID NO: 1).

[0044] Step 2: Design a DNA sequence for collagen expression (SEQ ID NO: 2) based on the codon preference of lactic acid bacteria. The specific sequence is as follows:

[0045] GGACGTCCTGGTCGTCCAGGTGAGCGAGGTTTACCAGGACCACCAGGGATTAAAGGGCCAGCAGGAATTCCAGGTTTCCCAGGAATGAAAGGACATCGTGGATTTGATGGTAGAAATGGTGAAAAAGGAGAAACTGGTGCACCTGGCTTAAAAGGTGAAAACGGGCTACCGGGAGAAAATGGAGCACCAGGC CCAATGGGACCTCGGGGCGCTCCTGGGGAACGTGGTCGCCCCGGCTTGCCCGGGGCTGCTGGAGCGCGAGGAAATGATGGAGCCAGAGGTTCTGACGGTCAACCTGGTCCTCCTGGTCCACCTGGAACAGCTGGTTTTCCAGGTTCACCGGGTGCCAAGGGCGAAGTTCATCATCATCATCACCATTAA(SEQ ID NO:2).

[0046] Step 3: Primer design, as shown in Table 1 below, the primer sequence contains two restriction sites: NcoI (CCATGG) and HindIII (AAGCTT).

[0047] Table 1

[0048]

[0049] Step 4: Using the DNA sequence fragment synthesized in step 2 as a template, the primers ColF and ColR designed in step 3 were used for PCR amplification to obtain a high-concentration DNA fragment, and then the DNA fragment and the pNZ8149 plasmid (purchased from Changsha Abiwei Biotechnology Co., Ltd.) were double-digested with restriction endonucleases NcoI and HindIII, respectively, and the DNA fragment and the plasmid were connected with T4 ligase to obtain the recombinant plasmid pNZ8149-ColⅢ, and the recombinant plasmid was transferred into lactic acid bacteria Lactococcus lactis NZ3900 (purchased from Changsha Abiwei Biotechnology Co., Ltd.) by electroporation to obtain the type III collagen expression strain NZ3900-ColⅢ.

[0050] Step 5: Use M17 medium to culture strain NZ3900-ColⅢ at 37℃ with shaking (100 rpm) for 14 hours, induce expression with 10μg / L Nisin (30℃, 10 hours), collect the cells, boil and lyse them, and then perform protein gel electrophoresis detection. The results are as follows: Figure 1 As shown, it shows that the target protein is highly expressed near the 12KDa position. The components of M17 medium are as follows: 5g / L soytone, 2.5g / L peptone, 2.5g / L casein peptone / enzyme hydrolyzed casein, 2.5g / L yeast extract powder, 5g / L beef extract powder, 5g / L lactose, 0.5g / L sodium ascorbate, 19g / L sodium β-glycerophosphate, and 0.25g / L magnesium sulfate.

[0051] Step 6: Perform western blot detection on the target protein after protein gel electrophoresis. The results are as follows: Figure 2 As shown, it was shown that a significant target band could be detected using the histidine tag antibody.

[0052] Obviously, the above embodiments of the present invention are only examples for clearly illustrating the present invention, and are not limitations on the implementation methods of the present invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is impossible to list all the implementation methods here. All obvious changes or modifications derived from the technical solution of the present invention are still within the protection scope of the present invention.

Claims

1. An isolated nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO: 2, or a sequence having 80% or more homology with the nucleotide sequence as shown in SEQ ID NO:

2.

2. The nucleic acid molecule according to claim 1, characterized in that The nucleic acid molecule encodes human type III collagen, and the human type III collagen has the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence shown in SEQ ID NO: 1 after one or more amino acids are added, deleted, replaced or modified.

3. A recombinant expression vector containing the nucleic acid molecule according to claim 1 or 2.

4. A host cell, characterized in that The host cell contains the nucleic acid molecule according to claim 1 or 2 or the recombinant expression vector according to claim 3.

5. The host cell according to claim 4, characterized in that The host cell is lactic acid bacteria, preferably Lactococcus lactis NZ3900 strain, Preferably, the host cell can express type III collagen, and the type III collagen has the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence shown in SEQ ID NO: 1 after one or more amino acids are added, deleted, replaced or modified.

6. A primer pair for PCR amplification of the nucleic acid molecule according to claim 1 or 2, the primer pair comprising: Forward primer: CTAGCCATGGGCGAAAATCTTTATTTTCAAGGAGGA (SEQ ID NO: 3), reverse primer: CAAGAAGCTTAACTTCGCCCTTGGCACC (SEQ ID NO: 4).

7. Use of the nucleic acid molecule according to claim 1 or 2, the recombinant expression vector according to claim 3, the host cell according to claim 4 or 5, and the primer pair according to claim 6 in producing human type III collagen.

8. A method for preparing human type III collagen, characterized in that: The method comprises the following steps: 1) introducing the nucleic acid molecule of claim 1 into a plasmid to obtain a recombinant plasmid; 2) Transforming the recombinant plasmid into host cells, culturing and inducing expression, and purifying to obtain human type III collagen.

9. The method according to claim 7, characterized in that: The nucleic acid molecule further comprises a nucleotide sequence encoding a tag, preferably a nucleotide sequence encoding at least one His tag; and / or The host cell is lactic acid bacteria, preferably Lactococcus lactis NZ3900 strain; and / or The plasmid is pNZ8149 plasmid; and / or The induction was performed using nisin.

10. Use of the type III collagen obtained by the preparation method of claim 8 in the preparation of medicines, cosmetics or health products for promoting new cell formation, wound healing and scar repair.